Peptide
AOD-9604
SaveA modified fragment of human growth hormone (amino acids 177-191) studied for fat-metabolism effects without the growth-promoting actions of full hGH.
Quick verdict
Failed to show significant weight loss in a phase IIb obesity trial. TGA-approved in Australia as a complementary medicine ingredient for osteoarthritis.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase IIb obesity trial did not meet primary endpoint. Some preclinical cartilage data. TGA listing in Australia is as a complementary medicine, not a prescription drug.
Benefits
- TGA-listed for osteoarthritis in oral form
- Does not appear to raise IGF-1 or cause hGH side effects
- Preclinical evidence for cartilage protection
Dosage notes
Oral doses of 1–2 mg/day used in Australian complementary medicine. Injectable protocols are not validated.
Side effects
- Injection-site reactions
- Headache
- Generally well tolerated in trials
Who should be cautious
Not FDA-approved. Gray-market injectable versions carry purity and sterility risks.
What this page cannot tell you
The largest human obesity trial was negative. Osteoarthritis claims rest on limited data.
Leaderboard scores
- Weight loss25
- Recovery25
Write a review
Sign in to write a review.